A Pharmacokinetic and Safety Evaluation of Single Oral Doses of Eszopiclone in Pediatric Subjects From 6 to 17 Years of Age with ADHD and Insomnia

Friday, October 21, 2011

Gary Maier, Ph.D., Sunovion Pharmaceuticals, Inc., Marlborough, MA

Jeffrey Blumer, M.D., University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH

Brigitte Robertson, M.D., Sunovion Pharmcaeuticals, Inc., Marlborough, MA, Afghanistan

Qiang Lu, Cognigen Corporation, Buffalo, NY

Jacqueline Zummo, Ph.D., Sunovion Pharmaceuticals, Inc., Marlborough, MA

Elizabeth Ludwig, Cognigen Corporation, Buffalo, NY


Please note that this schedule is subject to change. The Program Book distributed at the Annual Meeting will have final information on dates, times, and speakers for each presentation.

New Research Poster Presentation 4.29 A Pharmacokinetic and Safety Evaluation of Single Oral Doses of Eszopiclone in Pediatric Subjects From 6 to 17 Years of Age with ADHD and Insomnia